Colorectal cancer (CRC) remains a severe global public health challenge. Despite advances in diagnosis and treatment, long-term survival rates for CRC patients remain suboptimal. In recent years, research focus has shifted toward chemoprevention—using natural or synthetic substances to inhibit, delay, or reverse carcinogenesis—offering a proactive strategy to address this unmet medical need.
Mounting evidence identifies a "pathological triad" driving CRC development: oxidative stress, chronic inflammation, and mitochondrial dysfunction. At the core of this process lies the critical balance between NAD+ (nicotinamide adenine dinucleotide) and its reduced form, NADH. Dysregulation of the NAD+/NADH ratio is closely linked to metabolic disorders and cancer initiation, making interventions targeting NAD(H) metabolism a promising avenue for CRC prevention.
Groundbreaking Preclinical Study: NADH Inhibits Early Colon Carcinogenesis
A latest study published in Journal of Molecular Histology (October 2025) by an Algerian research team—titled "Moderate NADH supplementation prevents early colon carcinogenesis by modulating inflammation and oxidative stress in a mouse model"—provides compelling preclinical evidence that moderate NADH supplementation exerts significant chemopreventive effects in a 1,2-dimethylhydrazine (DMH)-induced mouse model of CRC.
Study Design & Methodology
The research team systematically evaluated NADH’s chemopreventive potential through a well-controlled animal study:
- Groups: Control (saline), DMH model (20 mg/kg DMH, once weekly), DMH + NADH (50 mg/kg, three times weekly), DMH + NADH (150 mg/kg, three times weekly), and NADH alone (50 mg/kg).
- Intervention Duration: 12 weeks.
- Key Outcome Measures:
- Precancerous lesions: Number and multiplicity of aberrant crypt foci (ACF).
- Histopathology: Colon tissue structure and dysplasia via HE staining.
- Systemic effects: Body weight changes and blood routine parameters.
- Oxidative stress: MDA (malondialdehyde), nitrite, SOD, GPX, CAT, and GSH levels.
- Inflammatory factors: Colonic concentrations of TNFα, IL17, and IFNγ.
Key Findings: NADH Exerts Multitargeted Chemopreventive Effects
1. Significant Inhibition of Precancerous Lesions (ACF)
The DMH model group developed a high number of ACFs—hallmark precancerous lesions in CRC. Moderate-dose NADH (50 mg/kg) supplementation reduced total ACF count by 53.48% (p 0001), while high-dose NADH (150 mg/kg) showed a weaker protective effect (39.27% reduction). This finding highlights a dose-dependent, non-linear response to NADH, with moderate doses yielding optimal efficacy.
2. Improved Histopathological Structure
DMH-induced colon tissue exhibited severe structural damage and high-grade dysplasia. NADH-treated groups—particularly the moderate-dose cohort—displayed crypt structures closer to normal, significantly reduced dysplasia, and partial preservation of goblet cells, indicating reversal of early morphological abnormalities.
3. Attenuation of Systemic Toxicity
NADH effectively mitigated DMH-induced weight loss, with the moderate-dose group showing the most pronounced benefit. Additionally, NADH prevented DMH-associated anemia (reductions in RBC and Hb) and leukocyte imbalance, maintaining hematopoietic system stability.
4. Restored Redox Homeostasis
DMH exposure led to a ~5.5-fold increase in the oxidative damage marker MDA, elevated nitrite levels, and a sharp decline in antioxidant enzymes (SOD, GPX, CAT) and GSH. NADH supplementation—especially at moderate doses—successfully reversed these changes, lowering oxidative stress markers and enhancing antioxidant defense capacity.
